Atossa Therapeutics, Inc. (ATOS)

Market Cap	145.88M
Revenue (ttm)	n/a
Net Income (ttm)	-29.69M
Shares Out	125.76M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,001,547
Open	1.190
Previous Close	1.200
Day's Range	1.150 - 1.210
52-Week Range	0.620 - 2.310
Beta	1.19
Analysts	Strong Buy
Price Target	6.13 (+428.45%)
Earnings Date	Aug 12, 2024

About ATOS

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2012
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: ATOS

Analyst Forecast

According to 3 analysts, the average rating for ATOS stock is "Strong Buy." The 12-month stock price forecast is $6.13, which is an increase of 428.45% from the latest price.

Price Target

$6.13

(428.45% upside)

Analyst Consensus: Strong Buy